Secretory Phospholipase A2 Receptor clinical trials
6 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
- Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
- A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
- A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
- Belimumab With Rituximab for Primary Membranous Nephropathy
- Atacicept in Multiple Glomerular Diseases
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “Secretory Phospholipase A2 Receptor” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.